Kateri Moore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kateri Moore has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Carlos-Filipe Pereira
Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden
10 shared publications Ihor R. Lemischka
Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
7 shared publicationsDmitri Papatsenko
Skoltech Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow 121205, Russia
5 shared publicationsChristoph Schaniel
Department of Cell, Developmental and Regenerative Biology Icahn School of Medicine at Mount Sinai, New York City New York
4 shared publicationsMichael G. Daniel
Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1496, New York, NY 10029, USA; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1496, New York, NY 10029, USA; The Graduate School of Biomedical Sciences; Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1496, New York, NY 10029, USA
4 shared publicationsXiaohong Niu
Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1496, New York, NY 10029, USA; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1496, New York, NY 10029, USA
4 shared publications
Latest Publications
- Open Access
- 1 April 2020
- Published by Elsevier in Stem Cell Reports
- Vol. 14 (4) , 561-574
Memory of Divisional History Directs the Continuous Process of Primitive Hematopoietic Lineage Commitment
- 1 April 2020
- Published by Elsevier in Stem Cell Reports
- Vol. 14 (4) , 561-574
Open AccessMemory of Divisional History Directs the Continuous Process of Primitive Hematopoietic Lineage Commitment
- 17 October 2019
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1466 (1) , 59-72
Induction of developmental hematopoiesis mediated by transcription factors and the hematopoietic microenvironment
The induction of hematopoiesis in various cell types via transcription factor (TF) reprogramming has been demonstrated by several strategies. The eventual goal of these approaches is to generate a product for unmet needs in hematopoietic cell transplantation therapies. The most successful strategies hew closely to clues provided from developmental hematopoiesis in terms of factor expression and environmental cues. In this review, we aim to summarize the TFs that play important roles in developmental hematopoiesis primarily and to also touch on adult hematopoiesis. Several aspects of cellular and molecular biology coalesce in this process, with TFs and surrounding cellular signals playing a major role in the overall development of the hematopoietic lineage. We attempt to put these elements into the context of reprogramming and highlight their roles.
- 17 October 2019
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1466 (1) , 59-72
Induction of developmental hematopoiesis mediated by transcription factors and the hematopoietic microenvironment
The induction of hematopoiesis in various cell types via transcription factor (TF) reprogramming has been demonstrated by several strategies. The eventual goal of these approaches is to generate a product for unmet needs in hematopoietic cell transplantation therapies. The most successful strategies hew closely to clues provided from developmental hematopoiesis in terms of factor expression and environmental cues. In this review, we aim to summarize the TFs that play important roles in developmental hematopoiesis primarily and to also touch on adult hematopoiesis. Several aspects of cellular and molecular biology coalesce in this process, with TFs and surrounding cellular signals playing a major role in the overall development of the hematopoietic lineage. We attempt to put these elements into the context of reprogramming and highlight their roles.
- Open Access
- 26 September 2019
- Published by Wiley in FEBS Letters
- Vol. 593 (23) , 3266-3287
Induction of human hemogenesis in adult fibroblasts by defined factors and hematopoietic coculture
Transcription factor (TF)‐based reprogramming of somatic tissues holds great promise for regenerative medicine. Previously, we demonstrated that the TFs GATA2, GFI1B, and FOS convert mouse and human fibroblasts to hemogenic endothelial‐like precursors that generate hematopoietic stem progenitor (HSPC)‐like cells over time. This conversion is lacking in robustness both in yield and biological function. Herein, we show that inclusion of GFI1 to the reprogramming cocktail significantly expands the HSPC‐like population. AFT024 coculture imparts functional potential to these cells and allows quantification of stem cell frequency. Altogether, we demonstrate an improved human hemogenic induction protocol that could provide a valuable human in vitro model of hematopoiesis for disease modeling and a platform for cell‐based therapeutics.Database: Gene expression data are available in the Gene Expression Omnibus (GEO) database under the accession number GSE130361.
- 26 September 2019
- Published by Wiley in FEBS Letters
- Vol. 593 (23) , 3266-3287
Open AccessInduction of human hemogenesis in adult fibroblasts by defined factors and hematopoietic coculture
Transcription factor (TF)‐based reprogramming of somatic tissues holds great promise for regenerative medicine. Previously, we demonstrated that the TFs GATA2, GFI1B, and FOS convert mouse and human fibroblasts to hemogenic endothelial‐like precursors that generate hematopoietic stem progenitor (HSPC)‐like cells over time. This conversion is lacking in robustness both in yield and biological function. Herein, we show that inclusion of GFI1 to the reprogramming cocktail significantly expands the HSPC‐like population. AFT024 coculture imparts functional potential to these cells and allows quantification of stem cell frequency. Altogether, we demonstrate an improved human hemogenic induction protocol that could provide a valuable human in vitro model of hematopoiesis for disease modeling and a platform for cell‐based therapeutics.Database: Gene expression data are available in the Gene Expression Omnibus (GEO) database under the accession number GSE130361.
- Open Access
- 1 December 2018
- Published by Elsevier in Cell Reports
- Vol. 25 (10) , 2821-2835.e7
Cooperative Transcription Factor Induction Mediates Hemogenic Reprogramming
- 1 December 2018
- Published by Elsevier in Cell Reports
- Vol. 25 (10) , 2821-2835.e7
Open AccessCooperative Transcription Factor Induction Mediates Hemogenic Reprogramming
- Open Access
- 16 December 2016
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 118,p. e54372
Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
The protocol described here details the induction of a hemogenic program in mouse embryonic fibroblasts via overexpression of a minimal ...
- 16 December 2016
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 118,p. e54372
Open AccessReprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
The protocol described here details the induction of a hemogenic program in mouse embryonic fibroblasts via overexpression of a minimal ...
- 1 March 2016
- Published by Elsevier in Developmental Cell
- Vol. 36 (5) , 525-539
Hematopoietic Reprogramming In Vitro Informs In Vivo Identification of Hemogenic Precursors to Definitive Hematopoietic Stem Cells
- 1 March 2016
- Published by Elsevier in Developmental Cell
- Vol. 36 (5) , 525-539
Hematopoietic Reprogramming In Vitro Informs In Vivo Identification of Hemogenic Precursors to Definitive Hematopoietic Stem Cells
- 1 March 2016
- Published by Elsevier in Trends in Cell Biology
- Vol. 26 (3) , 202-214
Making a Hematopoietic Stem Cell
- 1 March 2016
- Published by Elsevier in Trends in Cell Biology
- Vol. 26 (3) , 202-214
Making a Hematopoietic Stem Cell
- 8 January 2016
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1370 (1) , 24-35
Converting cell fates: generating hematopoietic stem cells de novo via transcription factor reprogramming
Even though all paradigms of stem cell therapy and regenerative medicine emerged from the study of hematopoietic stem cells (HSCs), the inability to generate these cells de novo or expand them in vitro persists. Initial efforts to obtain these cells began with the use of embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) technologies, but these strategies have yet to yield fully functional cells. Subsequently, more recent approaches involve transcription factor (TF) overexpression to reprogram PSCs and various somatic cells. The induction of pluripotency with just four TFs by Yamanaka informs our ability to convert cell fates and demonstrates the feasibility of utilizing terminally differentiated cells to generate cells with multilineage potential. In this review, we discuss the recent efforts undertaken using TF‐based reprogramming strategies to convert several cell types into HSCs.
- 8 January 2016
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1370 (1) , 24-35
Converting cell fates: generating hematopoietic stem cells de novo via transcription factor reprogramming
Even though all paradigms of stem cell therapy and regenerative medicine emerged from the study of hematopoietic stem cells (HSCs), the inability to generate these cells de novo or expand them in vitro persists. Initial efforts to obtain these cells began with the use of embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) technologies, but these strategies have yet to yield fully functional cells. Subsequently, more recent approaches involve transcription factor (TF) overexpression to reprogram PSCs and various somatic cells. The induction of pluripotency with just four TFs by Yamanaka informs our ability to convert cell fates and demonstrates the feasibility of utilizing terminally differentiated cells to generate cells with multilineage potential. In this review, we discuss the recent efforts undertaken using TF‐based reprogramming strategies to convert several cell types into HSCs.
- Open Access
- 30 May 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 444
Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment
The mechanisms allowing residual multiple myeloma (MM) cells to persist after bortezomib (Bz) treatment remain unclear. We hypothesized that studying the biology of bortezomib-surviving cells may reveal markers to identify these cells and survival signals to target and kill residual MM cells. We used H2B-GFP label retention, biochemical tools and in vitro and in vivo experiments to characterize growth arrest and the unfolded protein responses in quiescent Bz-surviving cells. We also tested the effect of a demethylating agent, 5-Azacytidine, on Bz-induced quiescence and whether inhibiting the chaperone GRP78/BiP (henceforth GRP78) with a specific toxin induced apoptosis in Bz-surviving cells. Finally, we used MM patient samples to test whether GRP78 levels might associate with disease progression. Statistical analysis employed t-test and Mann-Whitney tests at a 95% confidence. We report that Bz-surviving MM cells in vitro and in vivo enter quiescence characterized by p21CIP1 upregulation. Bz-surviving MM cells also downregulated CDK6, Ki67 and P-Rb. H2B-GFP label retention showed that Bz-surviving MM cells are either slow-cycling or deeply quiescent. The Bz-induced quiescence was stabilized by low dose (500nM) of 5-azacytidine (Aza) pre-treatment, which also potentiated the initial Bz-induced apoptosis. We also found that expression of GRP78, an unfolded protein response (UPR) survival factor, persisted in MM quiescent cells. Importantly, GRP78 downregulation using a specific SubAB bacterial toxin killed Bz-surviving MM cells. Finally, quantification of Grp78high/CD138+ MM cells from patients suggested that high levels correlated with progressive disease. We conclude that Bz-surviving MM cells display a GRP78HIGH/p21HIGH/CDK6LOW/P-RbLOW profile, and these markers may identify quiescent MM cells capable of fueling recurrences. We further conclude that Aza + Bz treatment of MM may represent a novel strategy to delay recurrences by enhancing Bz-induced apoptosis and quiescence stability.
- 30 May 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 444
Open AccessIdentification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment
The mechanisms allowing residual multiple myeloma (MM) cells to persist after bortezomib (Bz) treatment remain unclear. We hypothesized that studying the biology of bortezomib-surviving cells may reveal markers to identify these cells and survival signals to target and kill residual MM cells. We used H2B-GFP label retention, biochemical tools and in vitro and in vivo experiments to characterize growth arrest and the unfolded protein responses in quiescent Bz-surviving cells. We also tested the effect of a demethylating agent, 5-Azacytidine, on Bz-induced quiescence and whether inhibiting the chaperone GRP78/BiP (henceforth GRP78) with a specific toxin induced apoptosis in Bz-surviving cells. Finally, we used MM patient samples to test whether GRP78 levels might associate with disease progression. Statistical analysis employed t-test and Mann-Whitney tests at a 95% confidence. We report that Bz-surviving MM cells in vitro and in vivo enter quiescence characterized by p21CIP1 upregulation. Bz-surviving MM cells also downregulated CDK6, Ki67 and P-Rb. H2B-GFP label retention showed that Bz-surviving MM cells are either slow-cycling or deeply quiescent. The Bz-induced quiescence was stabilized by low dose (500nM) of 5-azacytidine (Aza) pre-treatment, which also potentiated the initial Bz-induced apoptosis. We also found that expression of GRP78, an unfolded protein response (UPR) survival factor, persisted in MM quiescent cells. Importantly, GRP78 downregulation using a specific SubAB bacterial toxin killed Bz-surviving MM cells. Finally, quantification of Grp78high/CD138+ MM cells from patients suggested that high levels correlated with progressive disease. We conclude that Bz-surviving MM cells display a GRP78HIGH/p21HIGH/CDK6LOW/P-RbLOW profile, and these markers may identify quiescent MM cells capable of fueling recurrences. We further conclude that Aza + Bz treatment of MM may represent a novel strategy to delay recurrences by enhancing Bz-induced apoptosis and quiescence stability.